Staying awake: OXR2 agonists compete in narcolepsy

With a Phase II readout from Centessa, the emerging ORX2 agonist class of therapies for narcolepsy now has three programs with proof-of-concept data. So far, Centessa’s early results are largely in line with those of its more advanced competitors.

On Wednesday, Centessa Pharmaceuticals plc (NASDAQ:CNTA) released its third-quarter earnings and reported Phase IIa data from its CRYSTAL-1 study of ORX750 in narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia (IH). While shares of Centessa dipped 18% after the announcement, they recovered to a 5% loss by day's end...